Safety and efficacy of the treatment of active-form Vitamin D application for meibomian gland dysfunction

Safety and efficacy of the treatment of active-form Vitamin D application for meibomian gland dysfunction - Treatment of active-form Vitamin D application for MGD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000029347

Enrollment

Registered

2017-09-29

Start date

2016-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

meibomian gland dysfunction

Interventions

active-form Vitamin D ointment application on the eye lids twice a day for 3 months

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Subjects diagnosed by the definition of MGD. Subjects having primary MGD or secondary MGD due to Stevens-Johnson syndrome, Ocular cicatricial pemphigoid, GVHD, and post-chemical or thermal bun.

Exclusion criteria

Exclusion criteria: Allergic reaction of active-form Vitamin D3 Subjects who have any ocular surface disease other than MGD

Design outcomes

Primary

Measure	Time frame
subjective symptom, slitlamp microscopy, tear function, non-contact meibography	—

Countries

Japan

Contacts

Public ContactSeika Den

Tokyo Dental College Ichikawa General Hospital Department of Ophthalmology

dens@tdc.ac.jp047-322-0151

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026